Endocrine Abstracts

Introdutcion: In recent years, thyroid microcarcinoma (TMC) predominates in the context of diagnosis and treatment of thyroid cancer. TMC has an excellent prognosis, its management is changed in the last few years, reducing surgical procedure and role of radioiodine ablation (RAI). Therefore, the question is what tests have a diagnostic value in patients with thyroid microcarcinoma after thyroidectomyThe aim of this study was to evaluate the role of 131 ...

A 67-year-old male with PTC (pT3N0) underwent a total thyroidectomy in February 2004. Subsequently he was treated with I-131 and radiotherapy (RT). Combined therapy did not normalize the serum thyroglobulin (TG). Because of elevated TG and persistent I-131 uptake in thyroid bed the patient received a total activity of 21275 MBq of I-131 in 4 years. The treatment was stopped in March 2007 due to a lack of I-131 uptake in the last post-therapeutic whole body scan (WBS) with stil...

Background: The activating somatic point mutation, BRAFV600E, is the most common genetic alteration observed in papillary thyroid carcinoma (PTC) but its oncogenic role in PTC has been extensively investigated. Numerous studies reported that BRAFV600E correlates with poor clinical outcome, whereas others have found no such association. It is estimated that BRAFV600E occurs in ~ 45–50% of PTC cases, but recent studies showed the more freque...

Introduction: In ATA recommendations (2016) a delayed risk stratification (DRS) system proposed by D.P. Momesso et al. was accepted as a diagnostic tool for the risk stratification of unfavorable clinical outcome and for monitoring the clinical outcome in differentiated thyroid cancer (DTC) patients treated without radioactive iodine (RAI).The aim of the study: To evaluate the DRS system in patients with low clinical stage (pT1aN0/Nx).<p class="abste...

Introduction: The activating BRAFV600E is the most common genetic alteration in PTC. There is a common belief that it can correlate with a more aggressive clinical course. The mutation of the CHEK2 gene impairs the repair processes of the damaged DNA. It can be expected that the coexistence of both mutations can be related to a worse clinical course.Aim: To assess the prevalence of the coexistence of the CHEK2 and BRAFV600E mutation...

Introduction: Still there is a discussion about the importance of diagnostic and prognostic relevance BRAFV600E mutation. The wide range of BRAFV600E mutation frequency (40–80%) doesn’t facilitate this task. Population diversity and genotyping methodology are suspected sources of differences seen in the mutation frequencies detected by different studies. The aim of this study was to assess the prevalence BRAF V600...

Introduction: BRAFV600E mutation constitutes 98–99% of all detected mutation in thyroid carcinoma. The remaining 2% are BRAF mutations detected in the vicinity of codon V600. Due to the low incidence not much is known about their importance for the development of papillary thyroid carcinoma (PTC). In addition, some of these mutations co-occur with the mutation BRAFV600E.Methods/design: The study prese...

Introduction: In recent years the growing rate of newly diagnosed papillary tyroid cancers (PTC) has been observed. Nowadays most of PTC are small (mostly <2cm in diameter) with no unfavourable patomorphological features, although the cases of incompletely resected PTC can still be encountered. Incomplete tumour resection, regardless of the presence of microscopic (R1) or macroscopic (R2) disease, after operation, is considered as a high-risk factor for PTC recurrence/pers...

Introduction: Selenium (Se) deficiency is a known risk factor for autoimmune thyroid diseases including Graves’ orbitopathy (GO).Objective: To determine the concentration of Se in serum and to determine the dependency of Se concentration on known markers of disease severity: the TRAB levels and the CAS (clinical activity score) in patients with GO.Material: 64 patients (50 women, 14 men; average age- 54.5 years) with active, m...

Introduction: An increase in the incidence of differentiated thyroid cancer (DTC) has been observed in recent decades. Despite the excellent prognosis, DTC patients remain on lifelong oncologic follow-up after treatment, due to fear of recurrence.Aim: Was to evaluate the frequency of real recurrence, defined as appearance of structural or biochemical disease after >12 month period of no evidence of disease (NED) in DTC patients.<p class="abstext"...